Summary

The global peptide synthesis market is estimated to reach USD 1.54 billion by 2031 from USD 0.98 billion in 2026, at a CAGR of 9.5% from 2026 to 2031. The market is projected to grow steadily over the forecast period, driven by the expanding pipeline of peptide-based therapeutics, rising demand for GLP-1 and other metabolic peptides, and broader use of synthetic peptides in oncology, diagnostics, and research. Growth is further supported by advances in automated solid-phase peptide synthesis, high-throughput platforms, specialized modification chemistries, and peptide purification and analytical technologies. However, high material and solvent consumption, synthesis complexity for long and difficult sequences, purification challenges, and the need for specialized technical expertise are expected to restrain broader market growth. The custom peptide synthesis services segment accounted for the largest share, by service type, in 2025. Based on service type, the peptide synthesis services market is segmented into custom peptide synthesis services, peptide engineering & modification services, peptide purification services, peptide analytical & characterization services, and peptide library preparation/synthesis services. In 2025, custom peptide synthesis services accounted for the largest market share, driven by growing outsourcing of standard, high-purity, modified, long, and complex peptide requirements. These services are widely used across drug discovery, therapeutic development, diagnostic research, antibody generation, and academic research workflows. Demand is further supported by increasing requirements for rapid turnaround, customized purity levels, difficult sequences, and specialized peptide formats. Their broad applicability across pharmaceutical & biotechnology companies, CROs & CDMOs, and academic & research institutes continues to support the segment’s leading position globally. Chemical synthesis segment accounted for the largest share of the peptide synthesis products market, by technique, in 2025. Based on technique, the peptide synthesis products market is segmented into chemical synthesis and biological synthesis. Chemical synthesis accounted for the largest market share in 2025, due to the widespread use of solid-phase peptide synthesis (SPPS) for research and therapeutic peptide production. SPPS offers established Fmoc- and Boc-based chemistries, compatibility with automation, sequence flexibility, and a broad ecosystem of synthesizers, resins, protected amino acids, and coupling reagents. Liquid-phase synthesis, hybrid approaches, and chemical ligation methods complement SPPS for selected fragments and complex sequences. The maturity of chemical synthesis workflows and their extensive use across pharmaceutical, biotechnology, CRO, and academic laboratories continue to support the segment’s leading position. Asia Pacific is expected to register the highest CAGR in the peptide synthesis market from 2026 to 2031. The peptide synthesis market, by region, is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Asia Pacific is estimated to grow at the highest CAGR during the forecast period, driven by expanding pharmaceutical and biotechnology R&D, growing peptide drug development, rising outsourcing of custom peptide synthesis, and improvements in research infrastructure. Growth is further supported by increasing adoption of automated peptide synthesizers, advanced purification and analytical platforms, and expanding demand for peptide therapeutics across China, India, Japan, South Korea, and Australia. Established regional suppliers and expanding global life-science operations continue to strengthen peptide synthesis capabilities across the region. The primary interviews conducted for this report can be categorized as follows: ・By Respondent: Supply Side (80%) and Demand Side (20%) ・By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%) ・By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%) Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), GenScript Biotech Corporation (China), Kaneka Corporation (Japan), Biotage AB (Sweden), Sartorius AG (Germany), Bachem Holding AG (Switzerland), CEM Corporation (US), Bio-Synthesis, Inc. (US), Biosynth (Switzerland), CSBio (US), GL Biochem (Shanghai) Ltd. (China), Mesa Laboratories, Inc. (US), Danaher Corporation (US), Chem-Impex International, Inc. (US), Advanced ChemTech (ACT) (US), Mimotopes Pty Ltd (Australia), Iris Biotech GmbH (Germany), AAPPTec, LLC (US), Enamine Ltd. (Ukraine), Intavis Peptide Services (Germany), JPT Peptide Technologies GmbH (Germany), Innovagen AB (Sweden), Peptide Protein Research Ltd. (UK), LifeTein LLC (US), Creative Peptides (US), Genemed Synthesis, Inc. (US), ChinaPeptides Co., Ltd. (China), and Beijing Scilight Biotechnology Co., Ltd. (China) are some of the key companies offering peptide synthesis products and services. Research Coverage This research report categorizes the peptide synthesis market by offering (products, services), product type (instruments, reagents & consumables), technique (chemical synthesis, biological synthesis), service type (custom peptide synthesis services, peptide engineering & modification services, peptide purification services, peptide analytical & characterization services, peptide library preparation/synthesis services), application (therapeutic applications, diagnostics applications, research applications), product end user (pharmaceutical & biotechnology companies, CROs & CDMOs, academic & research institutes, medical device companies, clinical & diagnostic laboratories), service end user (pharmaceutical & biotechnology companies, CROs & CDMOs, academic & research institutes, medical device companies, clinical & diagnostic laboratories), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. The scope of the report provides detailed information on major factors such as drivers, challenges, opportunities, and restraints that influence the growth of the peptide synthesis market. A comprehensive analysis of key industry players has been conducted to provide insights into their business overviews, product & services portfolios, and key strategies, including collaborations, partnerships, expansions, agreements, acquisitions, and recent developments in the peptide synthesis market. Key Benefits of Buying the Report This report offers a comprehensive overview of the peptide synthesis market. It aims to assess the market size and future growth opportunities across various segments. The report also features an in-depth competitive analysis of the major market players, including their company profiles, recent developments, and key market strategies: The report provides insights on the following pointers: ・Analysis of key drivers (surging demand for GLP-1 and other high-volume peptide therapeutics, rising complexity of peptide modalities requiring advanced synthesis and purification, expanding peptide drug pipelines and clinical development activity), restraints (high material consumption and waste generation in large-scale peptide synthesis, high cost and supply sensitivity of GMP-grade synthesis inputs), opportunities (rapid expansion of global GMP peptide manufacturing capacity, shift toward continuous-flow, hybrid, and solvent-efficient peptide synthesis technologies), and challenges (maintaining yield, purity, and batch consistency for complex peptides at scale) influencing the growth of the market. ・Product Development/Innovation: Detailed insights on newly launched products & services of the peptide synthesis market. ・Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions. ・Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the peptide synthesis market. ・Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), GenScript Biotech Corporation (China), Kaneka Corporation (Japan), Biotage AB (Sweden), Sartorius AG (Germany), Bachem Holding AG (Switzerland), CEM Corporation (US), Bio-Synthesis, Inc. (US), Biosynth (Switzerland), CSBio (US), GL Biochem (Shanghai) Ltd. (China), Mesa Laboratories, Inc. (US), Danaher Corporation (US), Chem-Impex International, Inc. (US), Advanced ChemTech (ACT) (US), Mimotopes Pty Ltd (Australia), Iris Biotech GmbH (Germany), AAPPTec, LLC (US), Enamine Ltd. (Ukraine), Intavis Peptide Services (Germany), JPT Peptide Technologies GmbH (Germany), Innovagen AB (Sweden), Peptide Protein Research Ltd. (UK), LifeTein LLC (US), Creative Peptides (US), Genemed Synthesis, Inc. (US), ChinaPeptides Co., Ltd. (China), and Beijing Scilight Biotechnology Co., Ltd. (China). The report also helps stakeholders understand trends in the peptide synthesis market and provides information on key drivers, restraints, challenges, and opportunities. A detailed analysis of the key industry players has been conducted to offer insights into their strategies, product & services launches, acquisitions, partnerships, collaborations, recent activities, investments, funding, brand/product/service comparisons, vendor evaluations, and financial metrics of the peptide synthesis sector.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 59
1.1 STUDY OBJECTIVES 59
1.2 MARKET DEFINITION 59
1.3 STUDY SCOPE 59
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 60
1.3.2 INCLUSIONS & EXCLUSIONS 61
1.3.3 YEARS CONSIDERED 63
1.3.4 CURRENCY CONSIDERED 63
1.4 STAKEHOLDERS 63
1.5 SUMMARY OF CHANGES 64
2 EXECUTIVE SUMMARY 65
2.1 MARKET HIGHLIGHTS & KEY INSIGHTS 65
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 67
2.3 DISRUPTIVE TRENDS IN PEPTIDE SYNTHESIS MARKET 68
2.4 HIGH-GROWTH SEGMENTS 69
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 70
3 PREMIUM INSIGHTS 71
3.1 PEPTIDE SYNTHESIS MARKET OVERVIEW 71
3.2 NORTH AMERICA: PEPTIDE SYNTHESIS MARKET, BY OFFERING 72
3.3 PEPTIDE SYNTHESIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 73
3.4 PEPTIDE SYNTHESIS MARKET SHARE, BY APPLICATION, 2026 VS. 2031 (%) 74
4 MARKET OVERVIEW 75
4.1 INTRODUCTION 75
4.2 MARKET DYNAMICS 75
4.2.1 DRIVERS 76
4.2.1.1 Surging demand for GLP-1 and other high-volume peptide therapeutics 76
4.2.1.2 Rising complexity of peptide modalities requiring advanced synthesis and purification 77
4.2.1.3 Expanding peptide drug pipelines and clinical development activity 77
4.2.2 RESTRAINTS 78
4.2.2.1 High material consumption and waste generation in large-scale solid-phase peptide synthesis 78
4.2.2.2 High cost and supply sensitivity of GMP-grade synthesis inputs 79
4.2.3 OPPORTUNITIES 79
4.2.3.1 Rapid expansion of global GMP peptide manufacturing capacity 79
4.2.3.2 Shift toward continuous-flow, hybrid, and solvent-efficient peptide synthesis technologies 79
4.2.4 CHALLENGES 80
4.2.4.1 Maintaining yield, purity, and batch consistency for complex peptides at scale 80
4.3 UNMET NEEDS & WHITE SPACES 80
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 81
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 82
5 INDUSTRY TRENDS 83
5.1 PORTER’S FIVE FORCES ANALYSIS 83
5.1.1 THREAT OF NEW ENTRANTS 84
5.1.2 THREAT OF SUBSTITUTES 84
5.1.3 BARGAINING POWER OF BUYERS 84
5.1.4 BARGAINING POWER OF SUPPLIERS 84
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 84
5.2 MACROECONOMIC OUTLOOK 85
5.2.1 INTRODUCTION 85
5.2.2 GDP TRENDS & FORECAST 85
5.2.3 TRENDS IN GLOBAL PEPTIDE SYNTHESIS MARKET 86
5.3 VALUE CHAIN ANALYSIS 86
5.4 ECOSYSTEM ANALYSIS 88
5.5 PRICING ANALYSIS 90
5.5.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT 91
5.5.2 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION 92
5.6 TRADE ANALYSIS 93
5.6.1 IMPORT SCENARIO (HS CODE 902720) 93
5.6.2 EXPORT SCENARIO (HS CODE 902720) 95
5.6.3 IMPORT SCENARIO (HS CODE 841933) 96
5.6.4 EXPORT SCENARIO (HS CODE 841933) 97
5.7 KEY CONFERENCES & EVENTS, 2026–2027 99
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 99
5.9 INVESTMENT & FUNDING ACTIVITY 100
5.10 IMPACT OF 2025 US TARIFFS ON PEPTIDE SYNTHESIS MARKET 101
5.10.1 INTRODUCTION 101
5.10.2 PRICE IMPACT ANALYSIS 101
5.10.3 IMPACT ON COUNTRY/REGION 102
5.10.3.1 North America 102
5.10.3.2 Europe 102
5.10.3.3 Asia Pacific 103
5.10.4 IMPACT ON END-USE INDUSTRIES 103
5.10.4.1 Pharmaceutical & biotechnology companies 103
5.10.4.2 CROs & CDMOs 104
5.10.4.3 Academic & research institutes, diagnostic labs, and other end users 104
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, AND INNOVATIONS 105
6.1 TECHNOLOGY ANALYSIS 105
6.1.1 KEY EMERGING TECHNOLOGIES 105
6.1.1.1 Solid-phase peptide synthesis (SPPS) 105
6.1.1.2 Liquid-phase peptide synthesis (LPPS) 106
6.1.1.3 Enzymatic peptide synthesis 106
6.1.1.4 Recombinant peptide synthesis 106
6.1.1.5 Continuous-flow peptide synthesis 107
6.1.2 COMPLEMENTARY TECHNOLOGIES 107
6.1.2.1 Analytical characterization & quality-control technologies 107
6.1.2.2 Purification & downstream processing technologies 107
6.1.2.3 Peptide ligation technologies 108
6.1.3 ADJACENT TECHNOLOGIES 108
6.1.3.1 Protein design & engineering 108
6.1.3.2 Synthetic biology/genetic-code engineering 108
6.2 TECHNOLOGY/PRODUCT ROADMAP 109
6.3 PATENT ANALYSIS 109
6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR PEPTIDE SYNTHESIS PATENTS 110
6.4 FUTURE APPLICATIONS 113
6.5 IMPACT OF AI/GEN AI ON PEPTIDE SYNTHESIS MARKET 113
6.5.1 BEST PRACTICES IN PEPTIDE SYNTHESIS WORKFLOW 114
6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN PEPTIDE SYNTHESIS MARKET 115
6.5.3 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS 115
6.5.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN PEPTIDE SYNTHESIS MARKET 115
7 SUSTAINABILITY & REGULATORY LANDSCAPE 117
7.1 REGIONAL REGULATIONS & COMPLIANCE 117
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 117
7.1.2 REGULATORY FRAMEWORK 120
7.1.3 INDUSTRY STANDARDS 121
7.2 SUSTAINABILITY INITIATIVES 121
7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 122
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 123
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 124
8.1 DECISION-MAKING PROCESS 124
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 125
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 125
8.2.2 KEY BUYING CRITERIA, BY END USER 125
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 127
8.4 UNMET NEEDS FROM END USERS 127
8.5 MARKET PROFITABILITY 128
9 PEPTIDE SYNTHESIS MARKET, BY OFFERING 129
9.1 INTRODUCTION 130
9.2 PRODUCTS 130
9.2.1 IN-HOUSE WORKFLOW CONTROL AND RECURRING PEPTIDE-SPECIFIC DEMAND TO DRIVE MARKET GROWTH 130
9.3 SERVICES 134
9.3.1 GROWING OUTSOURCING OF COMPLEX AND VARIABLE-VOLUME PEPTIDE PROJECTS TO SUPPORT MARKET GROWTH 134
10 PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE 138
10.1 INTRODUCTION 139
10.2 REAGENTS & CONSUMABLES 139
10.2.1 REAGENTS 143
10.2.1.1 Amino acid building blocks 147
10.2.1.1.1 Expanding use of protected and non-natural residues to drive demand for amino acid building blocks 147
10.2.1.2 Resins 151
10.2.1.2.1 Broader linker chemistry and high-throughput SPPS formats to support steady resin demand 151
10.2.1.3 Coupling reagents 154
10.2.1.3.1 Need for faster activation and lower side-reaction risk to sustain demand for advanced coupling chemistry 154
10.2.1.4 Peptide modification reagents 158
10.2.1.4.1 Half-life extension, targeting, and conjugation strategies to make modification reagents fastest-growing reagent category 158
10.2.1.5 Labeling reagents 161
10.2.1.5.1 Rising use of labeled peptides in imaging, diagnostics, binding studies, and assay development to expand demand 161
10.2.1.6 Protection & deprotection reagents 165
10.2.1.6.1 Orthogonal protecting strategies and pressure to reduce hazardous chemistry to shape product selection 165
10.2.1.7 Cleavage reagents 168
10.2.1.7.1 Continued SPPS use and demand for cleaner cleavage profiles to support recurring cleavage-chemistry purchases 168
10.2.1.8 Other reagents 172
10.2.2 CONSUMABLES 175
10.2.2.1 Higher synthesis throughput and purification workload to support steady recurring consumables demand 175
10.3 INSTRUMENTS 178
10.3.1 PEPTIDE SYNTHESIZERS 183
10.3.1.1 Peptide synthesizers, by type 188
10.3.1.1.1 Automated peptide synthesizers 188
10.3.1.1.2 Manual peptide synthesizers 192
10.3.1.2 Peptide synthesizers, by technology 195
10.3.1.2.1 Conventional-batch peptide synthesizers 195
10.3.1.2.2 Microwave-assisted peptide synthesizers 199
10.3.1.2.3 Hybrid peptide synthesizers 203
10.3.1.2.4 Other peptide synthesizers 206
10.3.2 PURIFICATION SYSTEMS 210
10.3.2.1 Higher crude-peptide complexity and throughput bottlenecks to increase demand for scalable purification platforms 210
10.3.3 ANALYTICAL & QUALITY CONTROL INSTRUMENTS 213
10.3.3.1 Impurity profiling, identity confirmation, and tighter peptide quality requirements to sustain analytical platform investment 213
10.3.4 LYOPHILIZATION EQUIPMENT 217
10.3.4.1 Need for stable dry peptide formats and scale-appropriate freeze-drying capacity to support demand 217
10.3.5 OTHER INSTRUMENTS 220
11 PEPTIDE SYNTHESIS PRODUCTS MARKET, BY TECHNIQUE 224
11.1 INTRODUCTION 225
11.2 CHEMICAL SYNTHESIS 225
11.2.1 SOLID-PHASE PEPTIDE SYNTHESIS (SPPS) 229
11.2.1.1 Automation, rapid iterative chemistry, and commercial-scale familiarity to sustain SPPS as largest chemical synthesis method 229
11.2.2 LIQUID-PHASE PEPTIDE SYNTHESIS (LPPS) 233
11.2.2.1 Solvent-efficiency improvements and large-scale economics to make LPPS fastest-growing chemical synthesis method 233
11.2.3 OTHER CHEMICAL METHODS 236
11.3 BIOLOGICAL SYNTHESIS 240
11.3.1 RECOMBINANT PEPTIDE PRODUCTION 244
11.3.1.1 Scalable microbial expression and established biologics infrastructure to keep recombinant production dominant within biological synthesis 244
11.3.2 ENZYMATIC PEPTIDE SYNTHESIS 247
11.3.2.1 High selectivity and lower-solvent ligation to position enzymatic synthesis as fastest-growing biological method 247
12 PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER 251
12.1 INTRODUCTION 252
12.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 252
12.2.1 EXPANDING PEPTIDE PIPELINES AND IN-HOUSE MANUFACTURING CAPABILITIES TO DRIVE MARKET GROWTH 252
12.3 CROS & CDMOS 256
12.3.1 RAPID OUTSOURCING AND CAPACITY EXPANSION TO MAKE CROS & CDMOS FASTEST-GROWING PRODUCT END-USER CATEGORY 256
12.4 ACADEMIC & RESEARCH INSTITUTES 259
12.4.1 DISCOVERY-LED PEPTIDE LIBRARIES AND GREATER ACCESS TO AUTOMATED BENCHTOP SYSTEMS TO SUSTAIN RESEARCH INSTITUTE DEMAND 259
12.5 MEDICAL DEVICE COMPANIES 263
12.5.1 PEPTIDE-FUNCTIONALIZED BIOSENSORS AND SURFACE-ENGINEERED DEVICES TO BROADEN SPECIALIZED DEMAND FOR MODIFIED SYNTHESIS PRODUCTS 263
12.6 CLINICAL & DIAGNOSTIC LABORATORIES 266
12.6.1 HIGHER ASSAY SPECIFICITY AND STANDARDIZED PEPTIDE REAGENTS TO SUPPORT ADOPTION IN CLINICAL AND DIAGNOSTIC LABORATORIES 266
13 PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE 270
13.1 INTRODUCTION 271
13.2 CUSTOM PEPTIDE SYNTHESIS SERVICES 271
13.2.1 FLEXIBLE SEQUENCE, PURITY, AND QUANTITY REQUIREMENTS TO KEEP CUSTOM PEPTIDE SYNTHESIS SERVICES LARGEST SERVICE CATEGORY 271
13.3 PEPTIDE ENGINEERING & MODIFICATION SERVICES 275
13.3.1 GROWING NEED FOR HALF-LIFE EXTENSION, TARGETING, AND CONJUGATION TO MAKE ENGINEERING & MODIFICATION SERVICES FASTEST-GROWING CATEGORY 275
13.4 PEPTIDE PURIFICATION SERVICES 278
13.4.1 MORE DIFFICULT PEPTIDE SEQUENCES AND TIGHTER PURITY SPECIFICATIONS TO SUSTAIN DEMAND FOR OUTSOURCED PURIFICATION 278
13.5 PEPTIDE ANALYTICAL & CHARACTERIZATION SERVICES 282
13.5.1 RISING MOLECULAR COMPLEXITY AND QUALITY EXPECTATIONS TO EXPAND PEPTIDE ANALYTICAL & CHARACTERIZATION OUTSOURCING 282
13.6 PEPTIDE LIBRARY PREPARATION/SYNTHESIS SERVICES 285
13.6.1 HIGH-THROUGHPUT SCREENING AND IMMUNE-MONITORING WORKFLOWS TO INCREASE ADOPTION OF PEPTIDE LIBRARY SERVICES 285
14 PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER 289
14.1 INTRODUCTION 290
14.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 290
14.2.1 BROAD OUTSOURCING ACROSS DISCOVERY AND DEVELOPMENT TO BOOST MARKET GROWTH 290
14.3 CROS & CDMOS 294
14.3.1 EXTERNAL CAPACITY, SPECIALIZED CHEMISTRY, AND NETWORK FLEXIBILITY TO MAKE CROS & CDMOS FASTEST-GROWING SERVICE END-USER CATEGORY 294
14.4 ACADEMIC & RESEARCH INSTITUTES 297
14.4.1 FLEXIBLE PROJECT-SCALE OUTSOURCING AND SPECIALIZED PEPTIDE FORMATS TO SUSTAIN DEMAND FROM ACADEMIC & RESEARCH INSTITUTES 297
14.5 MEDICAL DEVICE COMPANIES 301
14.5.1 PEPTIDE-FUNCTIONALIZED DEVICES AND BIOSENSORS TO INCREASE DEMAND FOR SPECIALIZED SYNTHESIS, MODIFICATION, AND CONJUGATION SERVICES 301
14.6 CLINICAL & DIAGNOSTIC LABORATORIES 304
14.6.1 ASSAY STANDARDIZATION AND CLINICAL-GRADE QUALITY REQUIREMENTS TO SUPPORT OUTSOURCED PEPTIDE SERVICES FOR DIAGNOSTIC LABORATORIES 304
15 PEPTIDE SYNTHESIS MARKET, BY APPLICATION 308
15.1 INTRODUCTION 309
15.2 THERAPEUTIC APPLICATIONS 309
15.2.1 THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION 313
15.2.1.1 Diabetes 313
15.2.1.1.1 Large established peptide classes and sustained need for high-purity analogs drive growth 313
15.2.1.2 Obesity 317
15.2.1.2.1 Late-stage dual- and triple-agonist pipelines and rapid commercial scale-up to make obesity fastest-growing therapeutic indication 317
15.2.1.3 Cancer 320
15.2.1.3.1 Targeted delivery, neoantigen programs, and radioligand development to deepen peptide-synthesis requirements in oncology 320
15.2.1.4 Autoimmune disease 324
15.2.1.4.1 Targeted oral peptides and antigen-specific immunomodulation to broaden peptide use in chronic autoimmune disorders 324
15.2.1.5 Other therapeutic indications 327
15.2.2 THERAPEUTIC APPLICATIONS, BY MOLECULE 331
15.2.2.1 Metabolic & hormonal peptides 331
15.2.2.1.1 High-volume incretin, insulin, and hormone-peptide demand to drive market growth 331
15.2.2.2 Peptide inhibitors 335
15.2.2.2.1 Improved oral delivery, structural constraint, and access to difficult protein interfaces to expand peptide inhibitor development 335
15.2.2.3 Peptide-drug conjugates (PDCs) 338
15.2.2.3.1 Targeted payload delivery and radioconjugate pipelines to make PDCs fastest-growing therapeutic molecule category 338
15.2.2.4 Peptide-based vaccines 342
15.2.2.4.1 Neoepitope discovery, immune monitoring, and personalized vaccine strategies to support high-diversity peptide synthesis demand 342
15.2.2.5 Other therapeutic modalities 345
15.3 RESEARCH APPLICATIONS 349
15.3.1 HIGH-THROUGHPUT DISCOVERY, BIOMARKER STUDIES, AND RECURRING CUSTOM-PEPTIDE USE TO SUSTAIN BROAD RESEARCH DEMAND BASE 349
15.4 DIAGNOSTIC APPLICATIONS 352
15.4.1 PEPTIDE-BASED ASSAY REAGENTS, IMAGING LIGANDS, AND COMPANION-DIAGNOSTIC DEVELOPMENT TO EXPAND SPECIALIZED DIAGNOSTIC DEMAND 352
16 PEPTIDE SYNTHESIS MARKET, BY REGION 356
16.1 INTRODUCTION 357
16.2 NORTH AMERICA 357
16.2.1 US 365
16.2.1.1 Dense peptide pipelines and domestic capacity to sustain market growth 365
16.2.2 CANADA 372
16.2.2.1 Biopharma manufacturing investment and research demand to support steady expansion 372
16.3 EUROPE 378
16.3.1 GERMANY 385
16.3.1.1 Integrated peptide manufacturing and strong chemical supply chains to support demand 385
16.3.2 UK 392
16.3.2.1 Research intensity and diagnostic peptide capability to support specialized demand 392
16.3.3 FRANCE 399
16.3.3.1 Expanding SPPS capacity to strengthen commercial peptide supply base 399
16.3.4 ITALY 405
16.3.4.1 Injectable manufacturing integration to support peptide development-to-product workflows 405
16.3.5 SPAIN 412
16.3.5.1 Research and specialty-pharma activity to sustain demand for imported synthesis solutions 412
16.3.6 REST OF EUROPE 418
16.4 ASIA PACIFIC 425
16.4.1 CHINA 435
16.4.1.1 Large-scale TIDES capacity and domestic supplier depth to accelerate market expansion 435
16.4.2 JAPAN 441
16.4.2.1 Advanced drug discovery and specialty peptide innovation to sustain high-value demand 441
16.4.3 INDIA 448
16.4.3.1 Cost-efficient CRDMO expansion and new peptide capacity to accelerate market growth 448
16.4.4 SOUTH KOREA 455
16.4.4.1 Biotech investment and long-acting peptide development to expand specialized demand 455
16.4.5 AUSTRALIA 462
16.4.5.1 Research-intensive institutions and biotech pipelines to sustain high-value peptide demand 462
16.4.6 REST OF ASIA PACIFIC 469
16.5 LATIN AMERICA 476
16.5.1 BRAZIL 484
16.5.1.1 Large research base and metabolic-disease focus to make Brazil core Latin American market 484
16.5.2 MEXICO 491
16.5.2.1 US-linked manufacturing and clinical research to support peptide synthesis demand 491
16.5.3 REST OF LATIN AMERICA 498
16.6 MIDDLE EAST 505
16.6.1 GCC COUNTRIES 513
16.6.1.1 Saudi Arabia 520
16.6.1.1.1 Localization initiatives and research funding to support rising peptide workflow adoption 520
16.6.1.2 UAE 527
16.6.1.2.1 Biotech hubs and regional distribution to strengthen access to peptide synthesis solutions 527
16.6.1.3 Rest of GCC Countries 534
16.6.2 REST OF MIDDLE EAST 541
16.7 AFRICA 548
16.7.1 RESEARCH-LED DEMAND AND IMPORT DEPENDENCE TO SHAPE MARKET 548
17 COMPETITIVE LANDSCAPE 556
17.1 OVERVIEW 556
17.2 KEY PLAYER STRATEGY/RIGHT TO WIN 556
17.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN PEPTIDE SYNTHESIS MARKET 557
17.3 REVENUE ANALYSIS, 2021–2025 558
17.4 MARKET SHARE ANALYSIS, 2025 559
17.5 COMPANY EVALUATION QUADRANT: KEY PLAYERS, 2025 561
17.5.1 STARS 561
17.5.2 EMERGING LEADERS 562
17.5.3 PERVASIVE PLAYERS 562
17.5.4 PARTICIPANTS 562
17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 564
17.5.5.1 Company footprint 564
17.5.5.2 Region footprint 565
17.5.5.3 Offering footprint 566
17.5.5.4 Product type footprint 567
17.5.5.5 Application footprint 568
17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 569
17.6.1 PROGRESSIVE COMPANIES 569
17.6.2 RESPONSIVE COMPANIES 569
17.6.3 DYNAMIC COMPANIES 569
17.6.4 STARTING BLOCKS 569
17.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 571
17.6.5.1 Detailed list of key startups/SMEs 571
17.6.5.2 Competitive benchmarking of key startups/SMEs 572
17.7 COMPANY VALUATION & FINANCIAL METRICS 573
17.7.1 FINANCIAL METRICS 573
17.7.2 COMPANY VALUATION 573
17.8 PRODUCT/SERVICE COMPARISON 574
17.9 COMPETITIVE SCENARIO 575
17.9.1 PRODUCT LAUNCHES 575
17.9.2 DEALS 576
17.9.3 EXPANSIONS 576
18 COMPANY PROFILES 577
18.1 KEY PLAYERS 577
18.1.1 THERMO FISHER SCIENTIFIC INC. 577
18.1.1.1 Business overview 577
18.1.1.2 Products & services offered 578
18.1.1.3 Recent developments 580
18.1.1.3.1 Product launches 580
18.1.1.3.2 Deals 581
18.1.1.3.3 Expansions 581
18.1.1.4 MnM view 581
18.1.1.4.1 Right to win 581
18.1.1.4.2 Strategic choices 582
18.1.1.4.3 Weaknesses & competitive threats 582
18.1.2 MERCK KGAA 583
18.1.2.1 Business overview 583
18.1.2.2 Products & services offered 584
18.1.2.3 Recent developments 586
18.1.2.3.1 Deals 586
18.1.2.3.2 Expansions 586
18.1.2.4 MnM view 587
18.1.2.4.1 Right to win 587
18.1.2.4.2 Strategic choices 587
18.1.2.4.3 Weaknesses & competitive threats 587
18.1.3 AGILENT TECHNOLOGIES, INC. 588
18.1.3.1 Business overview 588
18.1.3.2 Products & services offered 589
18.1.3.3 Recent developments 590
18.1.3.3.1 Product launches 590
18.1.3.4 MnM view 591
18.1.3.4.1 Right to win 591
18.1.3.4.2 Strategic choices 591
18.1.3.4.3 Weaknesses and competitive threats 591
18.1.4 GENSCRIPT BIOTECH CORPORATION 592
18.1.4.1 Business overview 592
18.1.4.2 Products & services offered 594
18.1.4.3 Recent developments 595
18.1.4.3.1 Expansions 595
18.1.4.4 MnM view 595
18.1.4.4.1 Right to win 595
18.1.4.4.2 Strategic choices 595
18.1.4.4.3 Weaknesses & competitive threats 595
18.1.5 KANEKA CORPORATION 596
18.1.5.1 Business overview 596
18.1.5.2 Products & services offered 597
18.1.5.3 Recent developments 599
18.1.5.3.1 Expansions 599
18.1.5.4 MnM view 599
18.1.5.4.1 Right to win 599
18.1.5.4.2 Strategic choices 599
18.1.5.4.3 Weaknesses & competitive threats 599
18.1.6 SARTORIUS AG 600
18.1.6.1 Business overview 600
18.1.6.2 Products & services offered 602
18.1.6.3 Recent developments 602
18.1.6.3.1 Expansions 602
18.1.7 BACHEM HOLDING AG 603
18.1.7.1 Business overview 603
18.1.7.2 Products & services offered 604
18.1.7.3 Recent developments 605
18.1.7.3.1 Deals 605
18.1.7.3.2 Expansions 606
18.1.8 BIOTAGE AB 607
18.1.8.1 Business overview 607
18.1.8.2 Products & services offered 607
18.1.8.3 Recent developments 608
18.1.8.3.1 Product launches 608
18.1.8.3.2 Deals 609
18.1.9 CEM CORPORATION 610
18.1.9.1 Business overview 610
18.1.9.2 Products & services offered 610
18.1.9.3 Recent developments 611
18.1.9.3.1 Product launches 611
18.1.10 BIO-SYNTHESIS, INC. 612
18.1.10.1 Business overview 612
18.1.10.2 Products & services offered 612
18.1.11 BIOSYNTH 614
18.1.11.1 Business overview 614
18.1.11.2 Products & services offered 614
18.1.11.3 Recent developments 615
18.1.11.3.1 Deals 615
18.1.11.3.2 Expansions 616
18.1.12 CSBIO 617
18.1.12.1 Business overview 617
18.1.12.2 Products & services offered 617
18.1.13 GL BIOCHEM (SHANGHAI) LTD. 618
18.1.13.1 Business overview 618
18.1.13.2 Products & services offered 618
18.1.14 MESA LABORATORIES, INC. 620
18.1.14.1 Business overview 620
18.1.14.2 Products & services offered 621
18.1.14.3 Recent developments 622
18.1.14.3.1 Product & service launches 622
18.1.14.3.2 Deals 623
18.1.15 DANAHER CORPORATION 624
18.1.15.1 Business overview 624
18.1.15.2 Products & services offered 625
18.1.15.3 Recent developments 627
18.1.15.3.1 Product launches 627
18.2 OTHER PLAYERS 628
18.2.1 CHEM-IMPEX INTERNATIONAL, INC. 628
18.2.2 ADVANCED CHEMTECH 629
18.2.3 MIMOTOPES PTY LTD. 630
18.2.4 IRIS BIOTECH GMBH 631
18.2.5 AAPPTEC, LLC 632
18.2.6 ENAMINE LTD. 634
18.2.7 INTAVIS PEPTIDE SERVICES GMBH 635
18.2.8 JPT PEPTIDE TECHNOLOGIES GMBH 636
18.2.9 INNOVAGEN AB 637
18.2.10 PEPTIDE PROTEIN RESEARCH LTD. 638
18.2.11 LIFETEIN LLC 639
18.2.12 CREATIVE PEPTIDES 640
18.2.13 GENEMED SYNTHESIS, INC. 641
18.2.14 CHINAPEPTIDES CO., LTD. 642
18.2.15 BEIJING SCILIGHT BIOTECHNOLOGY LTD. CO. 643
19 RESEARCH METHODOLOGY 644
19.1 RESEARCH DATA 644
19.1.1 SECONDARY DATA 645
19.1.1.1 Key secondary sources 645
19.1.1.2 Key data from secondary research 645
19.1.2 PRIMARY DATA 646
19.1.2.1 Key primary participants 646
19.1.2.2 Breakdown of primary interviews 646
19.1.2.3 Key data from primary sources 646
19.2 MARKET SIZE ESTIMATION 647
19.2.1 GLOBAL PEPTIDE SYNTHESIS MARKET ESTIMATION, 2025 647
19.2.1.1 Approach 1: Company revenue analysis-based estimation (bottom-up) 647
19.2.1.2 Approach 2: Primary research 649
19.2.1.2.1 Key industry insights 649
19.2.1.3 Approach 3: MnM repository analysis 649
19.2.2 SEGMENTAL MARKET SIZE ESTIMATION, 2025 650
19.3 MARKET GROWTH RATE PROJECTIONS 652
19.4 DATA TRIANGULATION 654
19.5 RESEARCH ASSUMPTIONS 655
19.6 RESEARCH LIMITATIONS & RISK ASSESSMENT 656
20 APPENDIX 657
20.1 DISCUSSION GUIDE 657
20.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 662
20.3 CUSTOMIZATION OPTIONS 664
20.4 RELATED REPORTS 664
20.5 AUTHOR DETAILS 665